Mesalazine

Where the papers sit

11 papers from the last 6 months study mesalazine directly · updated from PubMed 3 Oct 2026

• Drug Release and Permeation Testing

  Mesalamine formulation work is focusing on predictive control of dissolution, release and rectal permeation. Bicarbonate buffer molarity, capacity and pH are being tuned to distinguish delayed-release products, while particle size and crystal habit are linked to packing, wetting and dissolution. Xanthan and tragacanth provide alternative sustained-release mechanisms, and suppositories require dedicated in vitro permeation testing. The field is moving toward product-specific tests that better anticipate in vivo performance.

  5 papers · 45.5%

• Ulcerative Colitis Drug Delivery

  Ulcerative colitis maintenance is moving from conventional oral 5-ASA treatment toward colon-retentive and pH-responsive delivery. Mesalamine microparticles, linoleic acid-based nanocubosomes and glyceryl 1-oleate systems aim to release drug selectively in the colon. Comparative treatment evidence still includes switching between sulphasalazine and oral 5-aminosalicylic acid formulations. The central open question is whether improved targeting translates into more durable remission and fewer systemic effects.

  3 papers · 27.3%

• Targeted Inflammatory Bowel Therapy

  Inflammatory bowel therapy is moving toward localized delivery systems that concentrate treatment in diseased bowel. Thermo-responsive enemas and oral cobalt coordination microparticles represent different routes for targeted exposure, while diosmin studies implicate PI3K-Akt and NF-κB modulation. Formulation strategies are being evaluated alongside symptom and inflammatory responses rather than as simple drug substitutions. Whether these preclinical delivery and pathway findings improve clinical outcomes remains open.

  3 papers · 27.3%